Bradley Foster & Sargent Inc. CT Has $11,562,000 Position in Gilead Sciences Inc. (GILD)
Bradley Foster & Sargent Inc. CT decreased its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 5.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 138,604 shares of the biopharmaceutical company’s stock after selling 8,060 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Gilead Sciences were worth $11,562,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. First Financial Corp IN boosted its position in Gilead Sciences by 3.1% in the first quarter. First Financial Corp IN now owns 7,422 shares of the biopharmaceutical company’s stock worth $682,000 after buying an additional 225 shares in the last quarter. Van Cleef Asset Management Inc boosted its position in Gilead Sciences by 0.8% in the first quarter. Van Cleef Asset Management Inc now owns 61,797 shares of the biopharmaceutical company’s stock worth $5,677,000 after buying an additional 476 shares in the last quarter. BLB&B Advisors LLC bought a new position in Gilead Sciences during the first quarter worth about $268,000. Nicolet Bankshares Inc. boosted its position in Gilead Sciences by 2.5% in the first quarter. Nicolet Bankshares Inc. now owns 4,760 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 117 shares in the last quarter. Finally, BTR Capital Management Inc. boosted its position in Gilead Sciences by 5.3% in the first quarter. BTR Capital Management Inc. now owns 82,802 shares of the biopharmaceutical company’s stock worth $7,606,000 after buying an additional 4,165 shares in the last quarter. 77.94% of the stock is owned by institutional investors.
Gilead Sciences Inc. (NASDAQ:GILD) traded up 1.62% on Friday, reaching $79.12. 11,031,540 shares of the company’s stock traded hands. The firm has a market capitalization of $104.41 billion, a P/E ratio of 6.94 and a beta of 1.06. The stock has a 50-day moving average of $79.40 and a 200 day moving average of $85.53. Gilead Sciences Inc. has a 52 week low of $76.67 and a 52 week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period last year, the company earned $3.15 EPS. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.38%. Gilead Sciences’s payout ratio is currently 16.56%.
GILD has been the subject of a number of research analyst reports. Jefferies Group decreased their price target on shares of Gilead Sciences from $93.00 to $91.00 and set a “hold” rating for the company in a report on Wednesday, August 31st. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $108.00 price target on shares of Gilead Sciences in a report on Wednesday, August 31st. Leerink Swann set a $112.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, September 22nd. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $93.97 price objective on the stock in a research note on Tuesday, July 26th. Ten equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $105.00.
In other news, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $79.81, for a total transaction of $159,620.00. Following the transaction, the executive vice president now directly owns 64,122 shares in the company, valued at approximately $5,117,576.82. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO John F. Milligan sold 112,000 shares of the stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.